2019 IPO

Axcella Stock

Axcella is a biotechnology company providing therapeutics development solutions.

Sign up today and learn more about Axcella Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Axcella Stock

Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products.

Funding History

October 2013$10.8M
December 2013$0
May 2015$39.0M
February 2016$42.5M
November 2018$59.0M

Management

Founder

David Berry

Senior Vice President and Chief Medical Officer

Christopher Wright

CFO

Jeff Moore

President and Chief Executive Officer

William Hinshaw

President of R&D and Chief Scientific Officer

Peter Mueller

Co-Founder

Geoffrey von Maltzahn

Principal Research Fellow

Eugenio Ferrari

VP, Research

Michael Hamill

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo